,, a worldwide provider of scientific trial management solutions, today announced a new agreement with Cato Research Ltd., a full-service contract study organization cialis . Cato Study selected BioClinica’s medical trial management program system in its search for a best-in-class solution to raised serve its growing world-wide client base. We believe BioClinica CTMS is the best available solution supporting those requirements. Allen Cato, President of Cato Research. ‘One of our specialties is helping multifaceted development programs that want innovative regulatory and clinical strategies. BioClinica’s CTMS will assist us in this by helping us streamline our workflow and facilitate the scientific study processes.’ Related StoriesMirada Medical, BioClinica partner to extend oncology medical trialsOnconova uses BioClinica EDC, data management services to support scientific trialsBioClinica to showcase extended suite of services at upcoming global market conferences’BioClinica is pleased to be selected by Cato Research for its clinical trial management needs after this in-depth selection process,’ stated Peter Benton, President of BioClinica’s eClinical division.
Related StoriesScientists discover small molecule that may block growth of BRCA-deficient cancer cellsMD Anderson study reveals why chemotherapy medicines not effective for most pancreatic cancer patientsOvarian tumor patients with a history of oral contraceptive make use of have got better outcomesThey also discovered that drugs such as for example aspirin and ibuprofen, also reduced the risk of breast cancer however, not to the same degree. The experts believe the study highlights the potential of non-steroidal anti-inflammatory medications for the prevention of breast cancer. Harris and co-workers collected data on 323 patients with invasive breasts cancer shortly after their diagnosis. They matched the patients for age, county and race of home with 649 control individuals with no personal history of cancer.